Covance Purchases Equity Stake in Caprion ...(with headquarters in Princeton New Jerse...)

Date:12/16/2008

with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.5 billion, global operations in more than 20 countries, and more than 9,300 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

About Caprion Proteomics, Inc.

Caprion Proteomics is the leading provider of proteomics based services to the pharmaceutical industry. Caprion's proprietary proteomics discovery technology, CellCarta(R), is a gel-free, label-free mass spectrometry platform that enables a comprehensive, quantitative and robust measurement of the protein expression differences across large sets of biological samples. Caprion has been providing biomarker and target identification services since 2002, performing more than 30 large-scale biomarker projects for pharmaceutical industry clients such as Pfizer, Johnson & Johnson, Abbott Laboratories, Biogen Idec, Daiichi-Sankyo, Mitsubishi-Tanabe, Wyeth, AstraZeneca, Merck, Boehringer Ingelheim, ICOS, Bayer-Schering , EMD-Serono, Vertex, DebioPharm and Transgene. Caprion also has been awarded two major 5-year Biodefense proteomics research contracts in infectious disease with the NIH-NIAID, and was awarded the Frost & Sullivan Biomarker Technology award in 2007. Caprion Proteomics, a privately-held company, is majority owned by Great Point Partners, LP. For more information, please visit: www.caprion.com.

Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth and other financial results are forward-looking statements pursuant to the safe ha
'/>"/>

SOURCE Covance Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Covance and Lilly Finalize 10-Year, $1.6 Billion Strategic R&D Collaboration
2. Covance Decides to Pursue Its Original Preclinical Strategy in China
3. Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China
4. Covance to Present at The R.W. Baird 2008 Growth Stock Conference
5. Covance to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
7. Covance Inc. Invites You to Join the Webcast of Its Third Quarter 2007 Financial Results Conference Call
8. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
9. Cyprotex Purchases Applied Biosystems Sciex QTRAP(R) 5500 LC-MS/MS
10. Credit Suisse Repurchases Auction Rate Securities (ARS) From Rosetta Genomics
11. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes